|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment of long-lived assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Interest and other income | |||||
| Interest and other expense | |||||
| Total other income | |||||
| Net loss | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share, basic | |||||
| Net loss per share, diluted | |||||
| Total weighted average common stock outstanding, basic and diluted | |||||
| Other comprehensive loss: | |||||
| Unrealized gain (loss) on marketable securities | |||||
| Total comprehensive loss | |||||
Loading...